American Regent vs. Accord Healthcare: Trace Elements Patent Consolidation in Pharma Litigation

Case Overview

The Parties

Patents at Issue

This landmark case involved five U.S. patents covering formulation and/or method claims related to trace elements injection products — a technically specialized area involving the precise composition, stability, and administration of multi-element injectable solutions including zinc, copper, manganese, and selenium:

• • US11786548B2 (App. No. US17/365695)
• • US11998565B2 (App. No. US18/124391)
• • US11975022B2 (App. No. US18/482612)
• • US12150956B2 (App. No. US18/653608)
• • US12150957B2 (App. No. US18/672876)

The Verdict & Legal Analysis

Outcome

Case No. 2:24-cv-09600 was terminated by consolidation with a related Consolidated Action pending before the New Jersey District Court. The court’s order states: “good cause exists to consolidate the 24-9600 matter with the Consolidated Action.” No damages award, injunctive relief, or infringement finding was rendered in this docket.

Verdict Cause Analysis

The consolidation order reflects a judicial efficiency determination rather than a merits ruling. When multiple related patent infringement actions involving the same or overlapping parties, patents, and accused products are filed at different times, federal courts routinely consolidate them under Federal Rule of Civil Procedure 42(a) to avoid duplicative discovery, inconsistent rulings on claim construction, and inefficient use of court resources.

The existence of a pre-existing Consolidated Action suggests American Regent has been engaged in broader, coordinated litigation against Accord Healthcare — likely encompassing additional patents from its Tralement® and Multrys® portfolios, or involving earlier-filed complaints predating this October 2024 action. The addition of five patents via this filing — including two patents with application numbers filed in 2024 (US18/653608 and US18/672876), suggesting recently issued patents — indicates American Regent is actively expanding its patent assertions as new patents issue from its prosecution pipeline.

Legal Significance

Several legally significant elements emerge from this case’s structure:

• Continuation Patent Strategy: The presence of patents with application numbers filed across a multi-year window (2021 through 2024) strongly suggests American Regent is pursuing a continuation patent strategy, systematically obtaining new claims as its injectable trace elements technology matures. This approach — asserting both foundational and continuation patents simultaneously — creates layered infringement exposure for generic challengers.
• Multi-Patent Pharmaceutical Assertion: Asserting five patents across two related drug products in a single action maximizes litigation leverage and complicates invalidity defenses, as a challenger must overcome each patent independently.
• Consolidation as Strategic Signal: For defendants like Accord Healthcare, consolidation concentrates litigation risk into a single proceeding but also creates efficiencies in mounting unified invalidity and non-infringement defenses across all asserted patents.

Strategic Takeaways

For Patent Holders: American Regent’s approach illustrates the value of building layered patent portfolios through continuation filings. When new patents issue, promptly asserting them in consolidated litigation preserves rights and increases settlement leverage.

For Accused Infringers: Accord Healthcare faces consolidated claim construction and invalidity proceedings across five patents. Prioritizing inter partes review (IPR) petitions at the USPTO against the most commercially critical patents — particularly recently issued continuations — may provide parallel invalidity arguments outside district court.

For R&D Teams: Generic and biosimilar developers entering the parenteral nutrition injectables space must conduct rigorous Freedom to Operate (FTO) analyses accounting for continuation patent families, not just issued patents at the time of product development. A clean FTO landscape can change rapidly as continuation applications issue.